 Complete epithelial recovery was achieved by 67 of subjects receiving NEXAGON, as opposed to 27 receiving Vehicle aloneNEXAGON was well-tolerated demonstrating a safety profile similar to vehicleAmber plans to initiate the NEXPEDE-1 Phase 23 clinical trial in subjects with PCED of various etiologies in Q1 2023 Featured Image for Amber Ophthalmics, Inc. Featured Image ... The post Amber Ophthalmics Announces Positive Topline Phase 2 Data Evaluating NEXAGON for the Treatment of Persis... 